Safinamide: an add-on treatment for managing Parkinson’s disease

Heterogeneous expression of neurotransmitter deficits results from onset and progression of Parkinson’s disease. Intervals, characterized by reappearance of motor and associated certain nonmotor symptoms, determine the end of good tolerability and efficacy of oral levodopa therapy. These “OFF” state...

Descripción completa

Detalles Bibliográficos
Autor principal: Müller, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896660/
https://www.ncbi.nlm.nih.gov/pubmed/29670409
http://dx.doi.org/10.2147/CPAA.S137740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896660/
https://www.ncbi.nlm.nih.gov/pubmed/29670409
http://dx.doi.org/10.2147/CPAA.S137740

Ejemplares similares